Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer

被引:0
作者
Torhild Veen
Arezo Kanani
Dordi Lea
Kjetil Søreide
机构
[1] Stavanger University Hospital,Department of Gastrointestinal Surgery
[2] Stavanger University Hospital,Gastrointestinal Translational Research Unit, Laboratory for Molecular Medicine
[3] Stavanger University Hospital,Department of Pathology
[4] University of Bergen,Department of Clinical Medicine
来源
Cancer Immunology, Immunotherapy | 2023年 / 72卷
关键词
Immunotherapy; Immune checkpoint inhibitor; Mismatch repair deficiency; Colon cancer; Rectal cancer; Study design;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3135 / 3147
页数:12
相关论文
共 411 条
[1]  
Cervantes A(2023)Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up Ann Oncol 34 10-32
[2]  
Adam R(2022)Deficient mismatch repair/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment Eur J Cancer 175 136-157
[3]  
Roselló S(2021)Neoadjuvant immunotherapy in primary and metastatic colorectal cancer Br J Surg 108 1417-1425
[4]  
Arnold D(2020)Elevated microsatellite alterations at selected tetranucleotides (EMAST) in colorectal cancer is associated with an elderly, frail phenotype and improved recurrence-free survival Ann Surg Oncol 27 1058-1067
[5]  
Normanno N(2021)Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study Lancet Oncol 22 1002-1013
[6]  
Taïeb J(2022)Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial Lancet Gastroenterol Hepatol 7 38-48
[7]  
Taieb J(2022)PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer N Engl J Med 386 2363-2376
[8]  
Svrcek M(2020)Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers Nat Med 26 566-576
[9]  
Cohen R(2022)A comprehensive framework for early-onset colorectal cancer research Lancet Oncol 23 e116-e128
[10]  
Basile D(2021)Characteristics of early-onset vs late-onset colorectal cancer: a review JAMA Surg 156 865-874